p53 and bcl-2 immunohistochemical alterations in prostate cancer treated with radiation therapy
- 1 February 1998
- Vol. 51 (2) , 346-351
- https://doi.org/10.1016/s0090-4295(97)00636-5
Abstract
No abstract availableKeywords
This publication has 17 references indexed in Scilit:
- Cancer statistics, 1997CA: A Cancer Journal for Clinicians, 1997
- Correlation of genetic and immunodetection of TP53 mutations in malignant and benign prostate tissuesHuman Pathology, 1996
- Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancerHuman Pathology, 1995
- Immunohistochemical Determination of P53 Protein Nuclear Accumulation in Prostatic AdenocarcinomaJournal of Urology, 1994
- Wild-type p53 is a cell cycle checkpoint determinant following irradiation.Proceedings of the National Academy of Sciences, 1992
- Bcl-2 initiates a new category of oncogenes: regulators of cell deathBlood, 1992
- Deoxyribonucleic acid ploidy in the irradiated prostateWorld Journal of Urology, 1992
- Histologic changes of irradiated prostatic carcinoma diagnosed by transrectal ultrasoundHuman Pathology, 1992
- p53 Mutations in Human CancersScience, 1991
- Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life.Molecular and Cellular Biology, 1988